Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v3-EN Version v3-EN
Language English English
Date Updated 2021-05-04 2021-05-04
Drug Identification Number 02139510 02139510
Brand name SODIUM CHLORIDE INJECTION, USP SODIUM CHLORIDE INJECTION, USP
Common or Proper name Sodium Chloride Injection, USP 4 mEq/mL Maxivial® 200 mL Sodium Chloride Injection, USP 4 mEq/mL Maxivial® 200 mL
Company Name FRESENIUS KABI CANADA LTD FRESENIUS KABI CANADA LTD
Ingredients SODIUM CHLORIDE SODIUM CHLORIDE
Strength(s) 234MG 234MG
Dosage form(s) SOLUTION SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS INTRAVENOUS INTRAVENOUS
Packaging size 200 mL 200 mL
ATC code B05XA B05XA
ATC description I.V. SOLUTION ADDITIVES I.V. SOLUTION ADDITIVES
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date 2021-05-03 2021-05-03
Actual start date 2021-05-03 2021-05-03
Estimated end date 2021-07-31 2021-07-31
Actual end date
Shortage status Actual shortage Actual shortage
Company comments Fresenius Kabi Canada Ltd. regrets to advise that due to a production delay, we will be placing our Sodium Chloride Injection, USP 4 mEq/mL Maxivial® 200 mL on reduced allocation. Contract customers will be allocated 75% of their historical average monthly volumes, effective Monday, May 3, 2021. We will also be anticipating a backorder for this product effective June 1, 2021 until July 31, 2021. Please note that allocations of our Sodium Chloride Injection, USP 4 mEq/mL Maxivial® 100 mL have been increased to cover the 200mL demand. Fresenius Kabi Canada Ltd. regrets to advise that due to a production delay, we will be placing our Sodium Chloride Injection, USP 4 mEq/mL Maxivial® 200 mL on reduced allocation. Contract customers will be allocated 75% of their historical average monthly volumes, effective Monday, May 3, 2021. We will also be anticipating a backorder for this product effective June 1, 2021 until July 31, 2021. Please note that allocations of our Sodium Chloride Injection, USP 4 mEq/mL Maxivial® 100 mL have been increased to cover the 200mL demand.
Health Canada comments